Proof of concept in cardiovascular risk: The paradoxical findings in blood pressure and lipid abnormalities

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 437-442

  Fuchs, Flavio Danni ^a   Fuchs, Sandra Costa ^a   Moreira, Leila Beltrami ^a   Gus, Miguel ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Clinical trials; Hypertension; Lipoproteins; Proof of concept

Indexed keywords

ANACETRAPIB; ANTIHYPERTENSIVE AGENT; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PROBUCOL; TORCETRAPIB; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CONTROL; DISORDERS OF LIPID METABOLISM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LIPIDS; RISK ASSESSMENT; RISK FACTORS;

EID: 84867666043     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S32585     Document Type: Review

References (27)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
2. Lewington S, Whitlock G, Clarke R, et al; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-1839.
3. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement study follow-up (HERS II). JAMA. 2002;288(1): 49-57.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
6. Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular disease in middle-aged men. JAMA. 1991; 266(9):1225-1229.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
8. Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-381.
9. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992;305(6844):15-19.
10. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality: a quantitative rewiew of primary prevention trials. BMJ. 1990;301(6747):309-314.
11. Oliver MF. Prevention of coronary heart disease - propaganda, promises, problems, and prospects. Circulation. 1986;73(1):1-9.
12. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
13. Paciaroni M, Bogousslavsky J. Statins and stroke prevention. Expert Rev Cardiovasc Ther. 2009;7(10):1231-1243.
14. Ribeiro RA, Ziegelmann PK, Duncan BB, et al. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. Int J Cardiol. December 20, 2011. [Epub ahead of print.]
15. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
16. Shafiq N, Malhotra S, Pandhi P, Grover A. The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. J Negat Results Biomed. 2005;4:3.
17. Rahimi K, Majoni W, Merhi A, Emberson J. Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. Eur Heart J. February 3, 2012. [Epub ahead of print.]
18. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
19. Kastelein JJP, Akdim F, Stroes ESG, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(18):1431-1443.
20. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113-2122.
21. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
22. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):39-43.
23. Correa V Jr, Gus M, Fuchs FD. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? Expert Rev Cardiovasc Ther. 2010;8(6):775-779.
24. Messerli FH, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy - a meta-analysis. Am J Cardiol. 2008;101(3):319-325.
25. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305(9):913-922.
26. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-2415.
27. Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther. 2009;31(1):115-122.